We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New US legislation Aims to Phase Out Invasive Research on Great Apes

By LabMedica International staff writers
Posted on 14 Aug 2012
US Senate Environment and Public Works Committee recently approved the Great Ape Protection and Cost Savings Act (S. More...
810) and urged its passage in the full US Senate. Since Chimpanzees are the only great apes currently used in invasive research in the US, the new legislation will phase out such research on chimpanzees, end breeding of chimpanzees for invasive research purposes, and retire the 500 government-owned chimpanzees to sanctuary, saving approximately USD 25 million per year.

However, according to the act, the term Great Ape refers to Chimpanzees (Pan troglodytes), Bonobos (P. paniscus), Gorillas (Gorilla gorilla or G. beringei), Orangutans (Pongo pygmaeus or Pongo abelii), and Gibbons (Hylobatidae).

The bill was introduced by US Senators Maria Cantwell, Democrat-Washington, Susan Collins, Republican-Maine, and Bernard Sanders, Independent-Vermont.

S. 810 passed the committee by voice vote with the inclusion of an amendment that allows for invasive research on great apes in the event that a new, emerging, or reemerging disease requires their use. Approval for research will involve a transparent process that closely tracks the recommendations of a recent Institute of Medicine of the [US] National Academies (IOM; Washington DC, USA) report that concluded chimpanzees are largely unnecessary for current biomedical research.

The Great Ape Protection and Cost Savings Act was introduced in April 2011. A recent report by the Institute of Medicine and National Research Council could not identify any area of current biomedical research for which chimpanzee use is necessary. Moreover, the report pointed to several available alternatives to chimpanzee use and called for increased support for the development of more alternative research methods. Prior to the IOM report, approximately 80%-90% of chimpanzees in laboratories were not being used and instead are warehoused in laboratories at a high cost to US taxpayers. Sanctuaries can provide higher standards of care at a lower cost to taxpayers.

Related Links:

Institute of Medicine




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.